Anzeige
Meldung des Tages: Ist das DIE Rohstoff-Story des Jahres?

Nuvalent Aktie News

Aktie
WKN:  A3CWDU ISIN:  US6707031075 US-Symbol:  NUVL Branche:  Biotechnologie Land:  USA
112,29 $
+3,25 $
+2,98%
95,602 € 18:44:51 Uhr
Depot/Watchlist
Marktkapitalisierung *
5,06 Mrd. €
Streubesitz
-
KGV
-18,06
Index-Zuordnung
-

Nuvalent News

24.06.25 - PR Newswire
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC PR Newswire
23.06.25 - PR Newswire
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
Nuvalent Announces Timing of Pivotal Data for TKI Pre-​treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib PR Newswire
18.06.25 - PR Newswire
Nuvalent Appoints Christy Oliger to Board of Directors
Nuvalent Appoints Christy Oliger to Board of Directors PR Newswire
08.05.25 - PR Newswire
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results PR Newswire
29.04.25 - PR Newswire
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor PR Newswire
23.04.25 - PR Newswire
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting ...
01.04.25 - PR Newswire
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum PR Newswire
25.03.25 - PR Newswire
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
Nuvalent to Present New Preclinical Data on ALK-​Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 PR Newswire
28.02.25 - PR Newswire
Nuvalent to Participate in Upcoming March Investor Conferences
Nuvalent to Participate in Upcoming March Investor Conferences PR Newswire
27.02.25 - PR Newswire
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire

Newssuche

Videos

newspaper
14:40 Uhr
Wetter Trading: 82% Trefferquote im GBP dank Wetter Strategie!?!
Am Sonntag, den 25.1.26 findet unser Live-​Webinar der Wetter-​Trading Masterclass statt. Einen ... Mehr »